Arma Peptides publishes a Certificate of Analysis (CoA) for each batch, giving researchers a documented reference point for pH, sterility, and benzyl alcohol content ahead of use in any study protocol
Simple formulas: Fewer ingredients often mean fewer potential contaminants
For eligible patients with severe obesity, bariatric surgery may be considered as per NICE guidelines
Potential Risks and Side Effects The use of unapproved peptides like BPC-157 carries inherent risks
At this time, it is uncertain how participating beneficiaries will be able to maintain Medicare coverage of their GLP-1 medication for obesity after the Medicare GLP-1 Bridge ends at the end of 2027, pending further action from CMS to implement the BALANCE Model in Medicare Part D in 2028, as described below
Fortunately, Mojsovs work has, within the past year, been better appreciated and deservedly lauded